-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KEx1B5Cup2o9QXXyn5rB6RykPyq7e02UTRhOkzd86JzKyO4X/LQ6iJi35EjmliBu 0CeXkBtyH0s6E/8n6dHG7g== 0001072613-08-000336.txt : 20080213 0001072613-08-000336.hdr.sgml : 20080213 20080213150526 ACCESSION NUMBER: 0001072613-08-000336 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080213 DATE AS OF CHANGE: 20080213 GROUP MEMBERS: ABINGWORTH BIOVENTURES III A L.P. GROUP MEMBERS: ABINGWORTH BIOVENTURES III B L.P. GROUP MEMBERS: ABINGWORTH BIOVENTURES III C L.P. GROUP MEMBERS: ABINGWORTH BIOVENTURES III EXECUTIVES L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79884 FILM NUMBER: 08604012 BUSINESS ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Abingworth Management LTD CENTRAL INDEX KEY: 0001291892 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN BUSINESS PHONE: 44 20 7534 1508 MAIL ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN SC 13G/A 1 sch13ga_15710.txt ALNYLAM PHARMACEUTICALS, INC. ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________ SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1 (B) (C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(B) (Amendment No. 4)* Alnylam Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $0.01 par value per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 02043Q107 - -------------------------------------------------------------------------------- (CUSIP Number) December 31, 2007 - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ================================================================================ - ------------------- ----------------- CUSIP No. 02043Q107 13G Page 2 of 5 Pages - ------------------- ----------------- ITEM 1(A). NAME OF ISSUER: Alnylam Pharmaceuticals, Inc. (the "Issuer") -------------- ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: ----------------------------------------------- 300 Third Street, Cambridge, Massachusetts 02142 ITEM 2(A). NAME OF PERSONS FILING: ---------------------- Abingworth Management Limited ("Abingworth Management"), Abingworth Bioventures III A L.P. ("ABV III A"), Abingworth Bioventures III B L.P. ("ABV III B"), Abingworth Bioventures III C L.P. ("ABV III C"), and Abingworth Bioventures III Executives L.P. ("ABV III Executives" and together with ABV III A, ABV III B and ABV III C, the "ABV III Funds"). The foregoing individuals are each a "Reporting Person" and collectively referred to as the "Reporting Persons." ITEM 2(B). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: ----------------------------------------------------------- The business address for each Reporting Person is c/o Abingworth Management Limited, Princess House, 38 Jermyn Street, London, England SW1Y 6DN. ITEM 2(C). CITIZENSHIP: ----------- Abingworth Management is a corporation organized under the laws of England. ABV III A, ABV III B and ABV III C are limited partnerships organized under the laws of England. ABV III Executives is a limited partnership organized under the laws of Delaware. ITEM 2(D). TITLE OF CLASS OF SECURITIES: ---------------------------- Common Stock, $0.01 par value per share ITEM 2(E). CUSIP NUMBER: ------------ 02043Q107 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) ----------------------------------------------------------------- OR (C), CHECK WHETHER THE PERSON FILING IS A: -------------------------------------------- Not applicable. ITEM 4. OWNERSHIP. --------- Not applicable. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. -------------------------------------------- Each of the Reporting Persons has ceased to be the beneficial owner of more than five percent (5%) of the Issuer's outstanding Common Stock. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. ---------------------------------------------------------------- Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED ------------------------------------------------------------------ THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. ------------------------------------------------------------ Not applicable. Page 2 of 5 pages - ------------------- ----------------- CUSIP No. 02043Q107 13G Page 3 of 5 Pages - ------------------- ----------------- ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. --------------------------------------------------------- Not applicable. ITEM 9. NOTICE OF DISSOLUTION OF GROUP. ------------------------------ Not applicable. ITEM 10. CERTIFICATION. ------------- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 3 of 5 pages - ------------------- ----------------- CUSIP No. 02043Q107 13G Page 4 of 5 Pages - ------------------- ----------------- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 7, 2008 ABINGWORTH MANAGEMENT LIMITED By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III A L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III B L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III C L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III EXECUTIVES L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director Page 4 of 5 pages - ------------------- ----------------- CUSIP No. 02043Q107 13G Page 5 of 5 Pages - ------------------- ----------------- Exhibit 1 --------- AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Alnylam Pharmaceuticals, Inc. Date: February 7, 2008 ABINGWORTH MANAGEMENT LIMITED By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III A L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III B L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III C L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director ABINGWORTH BIOVENTURES III EXECUTIVES L.P. By: Abingworth Management Limited, its Manager By: /s/James Abell ------------------------------------- Name: James Abell Title: Executive Director Page 5 of 5 pages -----END PRIVACY-ENHANCED MESSAGE-----